DANIPHARM A/S: Financial statements 2023
CVR: 12335040
Source: annual report 2023, Danish Business Authority
01/07/2022 – 30/06/2023
DANIPHARM A/S (CVR 12335040) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 35,151,544 and a net result of DKK 5,390,779 compared with DKK 8,190,711 the year before. That is an increase of 0.6% compared with the year before. Equity in the 2023 report amounted to DKK 41,449,998. The solvency ratio was 47.6%. The company had 28 employees in the financial year.
- Gross Profit
- DKK 35,151,544
- Profit/Loss
- DKK 5,390,779
- Equity
- DKK 41,449,998
- Total Assets
- DKK 87,076,403
- Employees
- 28
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 35.2 mio. | 5.4 mio. | 41.4 mio. | 28 |
| 2022 | - | 34.9 mio. | 8.2 mio. | 36.1 mio. | 26 |
| 2021 | - | 29.4 mio. | 2.9 mio. | 29.9 mio. | 25 |
| 2020 | 91.6 mio. | 31.6 mio. | 5.8 mio. | 26.9 mio. | 22 |
| 2019 | - | 42.9 mio. | 16.3 mio. | 21.2 mio. | 21 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationAbout DANIPHARM A/S
DANIPHARM A/S is a Danish company of the type Aktieselskab based in Kastrup, founded in 1988. The company is registered under the industry Fremstilling af farmaceutiske råvarer. The management consists of Peter Rørvig. The board consists of Niels Ulrik Heine (chair), Helle Rørvig and Peter Rørvig. The company is owned by H&P Rørvig Holding A/S. The company has 24 employees (2018). In 2025, the company reported a gross profit of DKK 37,586,751 and a net result of DKK 13,717,304 compared with DKK 5,113,647 the year before. Equity in the 2025 report amounted to DKK 60,280,949.